Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab in Hepatocellular Carcinoma After Radical Surgery
NCT06851104Phase 2Terminated
- Sponsor
- Guangxi Medical University
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Primary endpoint: Recurrence-Free Survival at 2 years. Started Feb 2025; status: terminated.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06851104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851104.